GENE IDENTIFICATION
In some disorders, DNA There is a clinical role for this type of testing in at least 14 neuromuscular disorders 'and the number is rapidly increasing. Duchenne and Becker muscular dystrophies are the commonest with identifiable mutations in about 70%. The more severe Duchenne phenotype usually involves deletions that disrupt the translational reading frame of the mRNA triplet codons for the gene product, dystrophin. Although DNA testing alone cannot be used reliably to predict phenotype, characterisation of dystrophin allows alternative strategies for diagnosis when DNA testing is unhelpful or when questions remain in a particular family about the phenotype. DNA testing also plays an invaluable part in carrier detection and prenatal diagnosis.T hese advances have improved diagnosis and understanding of mechanisms in Duchenne muscular dystrophy and other muscular dystrophies4 but have not yet led to useful treatment: gene transfer therapy is a future prospect that awaits development of a viable mode of gene delivery.5
A new class of mutation, the trinucleotide repeat, has been identified and found to underlie the fragile X syndrome, myotonic dystrophy, Huntington's disease, and at least four other degenerative neurological diseases.' ' 6 7 In these diseases, the number of repeats of a base triplet sequence is increased. The expanded sequence is unstable in size and the phenomenon of anticipation occurs: age of onset is lowered and clinical manifestations or phenotype become more severe over successive generations because of progressive increase in size of the repeated segment. Parent of origin effects are marked in the transmission of such 'dynamic' mutations; this helps explain the occurrence of the congenital form of myotonic dystrophy only in children of affected mothers ( fig 1) ; of the juvenile form of Huntington's disease in the children of affected fathers; and of greater anticipation in the children of affected mothers in fragile X.' 6 7 Fragile X and myotonic dystrophy are multisystem disorders associated with large expansions of repeats and their pathological effect may be due to shutting off gene transcription. 2) .9 Neuronal death is also an important part of many neurological diseases whether inflammatory, traumatic, metabolic, or respiratory (hypoxic, ischaemic).°Many experimental studies suggest that asphyxial insults initiate cascades of events for a time after the insult ( fig 2) and also that intervention can rescue neurones.
Gluckman and Williams have divided the process into five time periods.10 Firstly, the preinsult period with state of maturity, metabolic status, and growth retardation influencing the effect of any subsequent insult. Secondly, there is the insult phase with some 'primary neuronal death'. Energy failure leads to widespread metabolic disruption, sodium and chloride influx, and accumulation of neurotransmitters and intracellular calcium. The latter may lead to inappropriate activation of normally suppressed programmed cell death (apoptosis). Thirdly, a 10 to 30 minute reperfusion phase is associated with release of cytotoxins including free radicals, prostanoids, and nitric oxide. Cellular energy is restored but neuronal activity remains depressed for some hours perhaps because of inhibitory neuromodulators such as adenosine, opioids, and y-aminobutyric acid. Fourthly, six to 12 hours after the insult there is a further period of oedema and metabolic disruption lasting 12 to 48 hours. This is associated with neuronal hyperexcitability and the transformation of microglia into activated macrophages followed by further release of nitric oxide and glutamate. This phagocytic activation may be central to secondary neuronal loss occurring at this time. Finally at 36 to 72 hours neurotrophic factors are induced, such as insulin-like growth factor, fibroblast growth factor, and calcitonin gene related peptide; these appear to be neuroprotective (fig 2) .
INTERVENTION STUDIES AND CLINICAL APPLICATION
Blockade of glutamate receptors, including the much studied N-methyl-D-aspartate subtype, reduces damage in some experimental situations. The pattern of cellular events differs between focal and global insults, according to the duration and timing of the asphyxial event" and maturity of the brain.'2 These variables influence the effect of interventions in experimental studies of asphyxia.
These experimental observations are relevant to clinical situations. Magnetic resonance spectroscopy studies in human infants have shown that acute asphyxia is often associated with a transient reduction in high energy substrates, followed several hours later by a prolonged fall associated with clinical encephalopathy." These observations support the concept of neuronal damage occurring after a delay of several hours after asphyxia. Raised The pedigree shows a family with a son (filled square) presenting with myotonic dystrophy (MD). Using a DNA probe specific for the MD gene, the two alleles of the gene are shown below each member of the family. The normal pattern is of two bands, one of 9 kb and one of 10 kb, as shown for the sister andfather of the proband. The mother and the proband both have an expansion (CTG) within the gene. In the mother the expansion is slight. This implies that she has MD but symptoms are likely to be mild and of late onset. The proband has a larger expansion shown by the upper andfainter ofhis two bands, which is substantially larger than 10 kb. The MD gene has expanded during transmission from mother to son.
encing programmed cell death 8(see below).
Trinucleotide repeats yet to be identified may also underlie a number of other clinically variable neurological diseases. 
Neuroimaging
The replacement of pneumoencephalography by computed tomography in the early 1970s led to a revolution in neurological and neurosurgical practice. Myelography was also improved by the introduction of safer water soluble dye as was angiography by digital subtraction angiography.
A revolution of comparable magnitude has begun with the arrival of magnetic resonance imaging (MRI) and the more recent functional magnetic resonance imaging (fMRI), which have the advantage of avoiding ionising radiation. The basic principles and clinical place of these techniques alongside computed tomography and the radionucleide techniques of positron emission tomography (PET) and single photon emission tomography (SPECT) are the subject of several recent reviews. 0(fig 3) . MRI has already established its superiority over computed tomography in detecting abnormalities in the spine or near the skull base particularly the posterior fossa.'9" It has also played an important part in managing epilepsy (see below)."2"23 28 Its role in the diagnosis of neurologically determined birth defects (figs [3] [4] [5] will continue to expand as technology is updated leading to more child friendly MRI units and better images. Age spe- cific limits of normality have been defined"2 and are addressed in the latest neuroradiology reference texts but will need to be refined as the technology to measure volumes and gyral patterns tempts enthusiasts into the zone of incidental findings.
The future role of fMRI in clinical practice is yet to be defined. Functional imaging is likely to play an important part in the assessment of Figure 4 Pachygyria, hemiparesis. Coronal Fourthly, the need to disseminate these advances to bring about changes in epilepsy management has led to examination of the 'model of care'. The Epilepsy Task Force has circulated to purchasers A Guide to Good Practice. 44 There are an increasing number of specialist epilepsy nurses, more written information for families is available, and there is a greater awareness of the central importance of patient and family perceptions of the condition. 45 Deficiencies in integrating epilepsy care remain. There are similar deficiencies in the care of children with other neurological disorders because of limited resources within individual districts, haphazard patterns of onward referral, and poor coordination between medical and other sectors. Nevertheless, the last five years have seen the consolidation of child development centres and increasing cooperation between the agencies involved in caring for children with neurological disorders. If the promise of molecular genetics and of neuroscience discussed above is fulfilled, further improvements in the model of care will be driven by an increase in the options for effective treatment.
